Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Disease × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 50 Carcinoma, Renal Cell 14 Neoplasm Metastasis 13 Neoplasms 12 Prostatic Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Uveal Melanoma 8 Pancreatic Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Lymphoma 7 Leukemia, Myeloid, Acute 7 Leukemia, Lymphocytic, Chronic, B-Cell 7 Carcinoma, Hepatocellular 7 Sarcoma 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Colorectal Neoplasms 6 Breast Neoplasms 6 Myelodysplastic Syndromes 5 Multiple Myeloma 5 Lymphoma, Non-Hodgkin 5 Triple Negative Breast Neoplasms 4 Small Cell Lung Carcinoma 4 Recurrence 4 Neuroblastoma 4 Myeloproliferative Disorders 4 Lymphoma, Large B-Cell, Diffuse 4 Lung Neoplasms 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Kidney Neoplasms 4 Hodgkin Disease 4

Interventions

Dexamethasone 2 vistusertib 1 ricolinostat 1 pomalidomide 1 irinotecan sucrosofate 1 daratumumab 1 bermekimab 1 atezolizumab 1 alovudine 1 TKM-080301 1 TIC10 compound 1 Prostatectomy 1 Pluvicto 1 Magnetic Resonance Spectroscopy 1 Lenalidomide 1 Ipilimumab 1 Ga(III)-DOTATOC 1 Fluorouracil 1 Cyclophosphamide 1 Blood Specimen Collection 1 (225)Ac-PSMA-617 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04855929 2024-11-08

ANV419-001

Anaveon AG

Phase 1 Completed

Disease, Lung Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡